These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 2990844)
21. [Metabolic effects of antacids and interactions with other drugs]. Gugler R; Musch E Z Gastroenterol; 1983 Mar; 21 Suppl():127-33. PubMed ID: 6858404 [TBL] [Abstract][Full Text] [Related]
23. Hypophosphatemic rickets with hypocalciuria following long-term treatment with aluminum-containing antacid. Foldes J; Balena R; Ho A; Parfitt AM; Kleerekoper M Bone; 1991; 12(2):67-71. PubMed ID: 2064842 [TBL] [Abstract][Full Text] [Related]
24. Some problems with antacids. Barry RE J Int Med Res; 1978; 6 Suppl 1():11-7. PubMed ID: 750251 [TBL] [Abstract][Full Text] [Related]
25. Hypermagnesemia and intestinal perforation following antacid administration in a premature infant. Brand JM; Greer FR Pediatrics; 1990 Jan; 85(1):121-4. PubMed ID: 2296480 [No Abstract] [Full Text] [Related]
26. Interaction of nutrients with antacids: a complication during enteral tube feeding. Valli C; Schulthess HK; Asper R; Escher F; Häcki WH Lancet; 1986 Mar; 1(8483):747-8. PubMed ID: 2870263 [No Abstract] [Full Text] [Related]
27. [Serum and urine electrolyte behavior under therapeutic dosage of a potent magnesium and aluminum hydroxide containing antacid]. Grünzig G; Lücker PW; Schnitker J Arzneimittelforschung; 1983; 33(2):258-62. PubMed ID: 6682667 [TBL] [Abstract][Full Text] [Related]
28. Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. Nassr N; Lahu G; Hünnemeyer A; von Richter O; Knoerzer D; Reutter F; Zech K; Hermann R J Clin Pharmacol; 2007 May; 47(5):660-6. PubMed ID: 17374735 [No Abstract] [Full Text] [Related]
29. Magnesium load induced by ingestion of magnesium-containing antacids. Lembcke B; Fuchs C Contrib Nephrol; 1984; 38():185-94. PubMed ID: 6713895 [No Abstract] [Full Text] [Related]
30. Pharmacology and clinical use of antacids. Green FW; Norton RA; Kaplan MM Am J Hosp Pharm; 1975 Apr; 32(4):425-9. PubMed ID: 236651 [TBL] [Abstract][Full Text] [Related]
31. Sodium content of maalox. Hazelwood D; Martinez DR Am J Hosp Pharm; 1976 Nov; 33(11):1127. PubMed ID: 998625 [No Abstract] [Full Text] [Related]
32. Metabolic alkalosis and hypermagnesemia following "non-absorbable" antacid therapy. Agarwal BN; Robertson FM Del Med J; 1986 Aug; 58(8):531-2. PubMed ID: 3758433 [No Abstract] [Full Text] [Related]
34. Effect of composition on the neutralizing properties of antacid preparations. Pawlaczyk J; Lutka A; Kokot Z Pharmazie; 1984 May; 39(5):334-6. PubMed ID: 6473495 [TBL] [Abstract][Full Text] [Related]
35. Antacid bezoar in a premature infant. Kaplan M; Ozeri Y; Agranat A; Brisk R; Eylath U Am J Perinatol; 1995 Mar; 12(2):98-9. PubMed ID: 7779206 [TBL] [Abstract][Full Text] [Related]
36. [A comparative evaluation of the antacid properties of the preparations Maalox and Almagel]. Grebenev AL; Sheptulin AA; Okhlobystin AV Ter Arkh; 1994; 66(8):44-7. PubMed ID: 7985154 [TBL] [Abstract][Full Text] [Related]
39. The mode of action and complications of Infant Gaviscon. Keipert JA Aust Paediatr J; 1979 Dec; 15(4):263-5. PubMed ID: 44677 [No Abstract] [Full Text] [Related]
40. Adverse effect of orally administered magnesium hydroxide on serum magnesium concentration and systemic acid-base balance in adult cattle. Kasari TR; Woodbury AH; Morcom-Kasari E J Am Vet Med Assoc; 1990 Mar; 196(5):735-42. PubMed ID: 2307611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]